Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance - Wikidata - awgldk - TriplyDB

Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance

Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance

http://www.wikidata.org/entity/Q24632641

about

Intestinal microbiota in functional bowel disorders: a Rome foundation report Clostridium difficile in the ICU: the struggle continues Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria Protective Effect of Carvacrol against Gut Dysbiosis and Clostridium difficile Associated Disease in a Mouse Model.Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota Newer antibacterials in therapy and clinical trials Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.Molecular epidemiology of Clostridium difficile at a medical center in Taiwan: persistence of genetically clustering of A⁻B⁺ isolates and increase of A⁺B⁺ isolates.An agent-based simulation model for Clostridium difficile infection control Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors.Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?The rising problem of antimicrobial resistance in the intensive care unit.Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection Is fidaxomicin worth the cost? An economic analysis.DETECTION, RIBOTYPING AND ANTIMICROBIAL RESISTANCE PROPERTIES OF CLOSTRIDIUM DIFFICILE STRAINS ISOLATED FROM THE CASES OF DIARRHEA.Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.Recurrent Clostridium difficile infection: what are the treatment options?Elderly patients with community-acquired pneumonia: optimal treatment strategies.Peptides as the next generation of anti-infectives.Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis.Homogeneous and digital proximity ligation assays for the detection of Clostridium difficile toxins A and B.Bibliometric Assessment of the Global Scientific Production of Nitazoxanide Delivering phage therapy per os: benefits and barriers.A Clostridium difficile Lineage Endemic to Costa Rican Hospitals Is Multidrug Resistant by Acquisition of Chromosomal Mutations and Novel Mobile Genetic Elements Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples.Toward the total synthesis of luminamicin; an anaerobic antibiotic: construction of highly functionalized cis-decalin containing a bridged ether moiety.Effective Sequestration of Clostridium difficile Protein Toxins by Calcium Aluminosilicate Effects of cyclic lipodepsipeptide structural modulation on stability, antibacterial activity, and human cell toxicity.Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases.Concordance of the SHEA-IDSA severity classification for Clostridium difficile infection and the ATLAS bedside scoring system in hospitalized adult patients.In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs.Rifaximin in the treatment of recurrent Clostridium difficile infection.Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection.Efficacy of an Optimised Bacteriophage Cocktail to Clear Clostridium difficile in a Batch Fermentation Model.A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment.

P2860

Q24631357-3D183401-7FD7-4187-915F-27D595BB6102 Q26823000-4F7E9CF0-ECEF-462E-AF46-3166107F0487 Q26863225-732F81DE-8EE4-4C23-B925-D9744960BDD1 Q33586133-F675843E-8044-4B7B-81E8-D105B087EAA2 Q33958376-4DA64556-F869-4503-B82E-3792368D72AD Q34097514-9B45C3C4-39E6-4865-A7F9-B15F04C271AE Q34488329-2F064710-187E-43C5-8F18-F7128263023B Q34710552-42E25CAD-39C9-4FC5-804B-A2E3769EAA88 Q35014457-56D034EB-6440-4C38-AD44-D65C2F88B08E Q35031203-B4FEDAC3-5888-442B-8014-17039FAB343B Q35044119-1187842A-9335-414E-9F00-E1225748F04A Q35332572-72374B73-A4A9-48FF-B6D1-A0C6797FE4DD Q35491398-E0D44C22-05C6-4CFB-BAE6-87B4734875A7 Q35595833-1A9DDB3B-5748-4BB6-9BA2-D64E10ED9DB3 Q36071524-3E42AC1F-EA28-4009-8A0C-F5962174C4B6 Q36075879-21D00145-1F5F-499E-84F8-D65D30BFED48 Q36377350-F095DF83-B52A-48A6-AE9C-81F68944AFFB Q37037009-C1391355-8212-466E-A444-A5EC7EEF633E Q37491761-76B2C790-0BF9-4405-8CAF-78D61D6014BF Q37838785-E6CB4639-CCDF-4E5B-970F-32E37A5124E1 Q37875055-F5752FE8-F9FC-411A-BA4C-093BEC1B7095 Q37896600-72D19A7D-F226-437F-9242-E34D294817C7 Q38086871-4B452154-BBD9-433B-95BA-C66EA78B3A89 Q38107547-6FDC5290-FF6F-4CC2-BBDB-82109EBDCDBE Q38289720-EA42CD85-1045-4C43-9822-03625202F016 Q38744585-1005210C-35BD-41EF-BC01-F615F7C0C1E3 Q39019401-33AC815F-304E-41FC-8CAF-5B8F2E5A2971 Q39382890-54874AE4-AC99-4D7C-B4AE-F7739E5711F5 Q39422769-D384EB5F-397C-4298-B1B6-45B8FCCAC17B Q40147516-30F302A3-8C80-4D99-B323-FE0513890626 Q41120077-D660C921-EB3B-43BA-AC98-85128793EB30 Q41444760-1E0653AA-FB97-4452-B178-D446D861395F Q42097408-C57AFD17-00ED-4CB1-A5AA-F0450B66263F Q42201627-639C0D84-0F9F-4FF2-9860-7C9986836C34 Q42695041-D6E5C294-815F-4D37-84D7-426BDBC46D9B Q43886607-61AE9A36-FFE8-4DDF-8691-EE2DDF69BD09 Q46549136-AAE925A9-8E4C-4911-B9C3-8FB4CEE678E8 Q47707104-7A5EAB9C-21C3-4FE1-965F-769C5D5F0CF9 Q50041908-CB811CC4-1583-454E-8E65-849C914F79C6 Q50608427-5A99C82E-33BA-4F6E-9641-77E4B1E9EB1B

P2860

Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance

http://www.wikidata.org/entity/Q24632641

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Clostridium difficile infectio ...... ions and antibiotic resistance

@ast

Clostridium difficile infectio ...... ions and antibiotic resistance

@en

Clostridium difficile infectio ...... ions and antibiotic resistance

@nl

type

label

Clostridium difficile infectio ...... ions and antibiotic resistance

@ast

Clostridium difficile infectio ...... ions and antibiotic resistance

@en

Clostridium difficile infectio ...... ions and antibiotic resistance

@nl

prefLabel

Clostridium difficile infectio ...... ions and antibiotic resistance

@ast

Clostridium difficile infectio ...... ions and antibiotic resistance

@en

Clostridium difficile infectio ...... ions and antibiotic resistance

@nl

P1433

Q24632641-D4B9FCE2-8C9E-4A39-B4DC-3B0E4BE8903B

P1476

Q24632641-80861F9D-FD6E-4009-8E69-ED9236B04B7B

P2093

Q24632641-52B6400D-6465-48D2-A217-A4BDD027D569

Q24632641-82EB4091-D8C7-485A-A9D9-13AB2E321CED

Q24632641-90FF3F9D-45FA-4F10-B717-A86810E5BE10

Q24632641-99639C4B-8133-4D31-A0BF-142D4E40DE2D

Q24632641-BEA8E015-8BBF-4398-BF84-C860A585CF7A

Q24632641-C164096D-E005-4BD5-A9EB-84D09E461ED5

P2860

Q24632641-03661EB4-F1BD-48D3-BB10-4F18BFEFDE77

Q24632641-040AF0E8-7A95-49BE-8468-DC86A9250C14

Q24632641-10809644-3857-4185-A6E1-BA22BDC700B0

Q24632641-16296B08-E4C3-49E8-A00E-175E49C55D26

Q24632641-1CFDEB82-D088-4AE8-980E-20BA7B7D2EAD

Q24632641-2622C2D8-EED1-43A2-9C92-E047FB4E948D

Q24632641-2D2EE276-105C-4927-A2AF-E945B8185773

Q24632641-2DAB2CA1-115E-4E34-800E-E74C605C5688

Q24632641-2F471D66-7BC8-467B-9777-DD23F7C07973

Q24632641-32081E78-0397-4704-B35F-CF518CB2FBD2

P304

Q24632641-0DEF61C7-C949-448C-AA25-C3F458258298

P31

Q24632641-3C7CECF3-C9DC-4248-B5DE-48750216FB32

P3181

Q24632641-BCDB807A-4F84-4895-947E-6871BD240B64

P356

Q24632641-3FABCC15-6C43-4003-8781-54051C8B32F2

P407

Q24632641-109104AA-FB5C-4EBA-A401-42EC4B94F39B

P433

Q24632641-152FBF0F-183E-44FE-A2B2-13A795B2E275

P478

Q24632641-672AD188-E789-4304-B72D-553EEF8B11A5

P50

Q24632641-5E77BD3D-17C6-4EDD-B5E0-EF7126C01DAA

P577

Q24632641-E297C68A-8877-437E-9A3A-15251A12EA02

P5875

Q24632641-FD0F55B9-C704-4735-A194-2CC1D0E6A4E6

P698

Q24632641-38F89593-AEA3-43CB-96F6-8787B14E79AE

P921

Q24632641-8CC9FFF5-DE7F-4102-A2F2-C5EC51C6A594

Q24632641-96293912-E029-44BD-A364-62360354A772

P932

Q24632641-152B1079-A5CD-4FA5-907C-4555EF8E4105

P3181

P356

P1433

Expert Review of Anti-infective Therapy

P1476

Clostridium difficile infectio ...... ions and antibiotic resistance

@en

P2093

Dhara Shah

http://www.w3.org/2001/XMLSchema#string

Hoonmo L Koo

http://www.w3.org/2001/XMLSchema#string

Kevin W Garey

http://www.w3.org/2001/XMLSchema#string

Minh-Duc Dang

http://www.w3.org/2001/XMLSchema#string

Rodrigo Hasbun

http://www.w3.org/2001/XMLSchema#string

Zhi-Dong Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia

Nitazoxanide: a review of its use in the treatment of gastrointestinal infections

Nitazoxanide for the treatment of Clostridium difficile colitis.

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.

Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI).

High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

P304

555-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3774299

http://www.w3.org/2001/XMLSchema#string

P356

10.1586/ERI.10.28

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Herbert L. DuPont

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44585643

http://www.w3.org/2001/XMLSchema#string

P698

20455684

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile

antibiotic resistance

P932

3138198

http://www.w3.org/2001/XMLSchema#string